Zoetis (NYSE:ZTS) Cut to Hold at Leerink Partnrs

Leerink Partnrs cut shares of Zoetis (NYSE:ZTS) from a strong-buy rating to a hold rating in a report released on Thursday,Zacks.com reports. Leerink Partnrs also issued estimates for Zoetis’ Q3 2025 earnings at $1.69 EPS, Q3 2025 earnings at $1.69 EPS and FY2025 earnings at $6.25 EPS.

Several other research firms have also recently commented on ZTS. UBS Group dropped their price objective on Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 7th. Piper Sandler increased their price objective on Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a research report on Monday, May 12th. Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and dropped their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $180.00 to $155.00 in a research report on Thursday. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $204.63.

Zoetis Price Performance

ZTS opened at $148.61 on Thursday. The stock has a fifty day simple moving average of $160.77 and a two-hundred day simple moving average of $161.43. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12. The company has a market cap of $66.16 billion, a price-to-earnings ratio of 26.68, a price-to-earnings-growth ratio of 2.46 and a beta of 0.91. Zoetis has a 12-month low of $139.70 and a 12-month high of $200.33.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The firm had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.20 billion. During the same period in the prior year, the firm posted $1.38 earnings per share. The company’s quarterly revenue was up 1.4% on a year-over-year basis. Research analysts predict that Zoetis will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.35%. The ex-dividend date is Friday, July 18th. Zoetis’s payout ratio is 35.91%.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the business’s stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the transaction, the executive vice president owned 15,129 shares in the company, valued at $2,571,930. The trade was a 4.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.18% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zoetis

A number of large investors have recently bought and sold shares of the business. Nova Wealth Management Inc. bought a new stake in Zoetis during the 1st quarter valued at $25,000. 1248 Management LLC bought a new stake in Zoetis during the 1st quarter valued at $27,000. Saudi Central Bank bought a new stake in Zoetis during the 1st quarter valued at $29,000. Navigoe LLC bought a new stake in Zoetis during the 4th quarter valued at $30,000. Finally, Cornerstone Planning Group LLC raised its position in shares of Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after acquiring an additional 88 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.